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ABSTRACT
Hypoxic tumor microenvironment (HTM) is considered to promote metabolic 
changes, oncogene activation, and epithelial mesenchymal transition, and resistance 
to chemo- and radio-therapy, all of which are hallmarks of aggressive tumor behavior. 
Cancer cells within the HTM acquire phenotypic properties that allow them to 
overcome the lack of energy and nutrients supply within this niche. These phenotypic 
properties include activation of genes regulating glycolysis, glucose transport, 
acidosis regulators, angiogenesis, all of which are orchestrated through the activation 
of the transcription factor, HIF1A, which is an independent marker of poor prognosis. 
Moreover, during the adaptation to a HTM cancer cells undergo deep changes in 
mitochondrial functions such as “Warburg effect” and the “reverse Warburg effect”.
This review aims to provide an overview of the characteristics of the HTM, with 
particular focus on novel therapeutic strategies currently in clinical trials, targeting 
the adaptive response to hypoxia of cancer cells.
HYPOXIA AND THERAPEUTIC 
TARGETS
Anti-angiogenesis agents and cancer therapy
During the growth of a solid neoplasia, the tumor 
microenvironment (TM) undergoes biochemical changes 
that include depletion of glucose, bicarbonate, O2 (i.e. 
hypoxia and anoxia), high levels of lactate and adenosine 
and low pH values [1, 2]. As a response to hypoxia and 
nutrient deficiencies, cells activate angiogenesis, that is 
the development of new blood vessels sprouting from 
the existing ones [3-6]. However, neo-angiogenesis 
yields immature vessels with functional and structural 
alterations, leading to an irregular blood flow, which 
fails to provide enough oxygen to each cancer cell and 
the TM remains, essentially, hypoxic [7, 8]. It has been 
thought that blocking the oxygen supply could be a 
valid therapeutic strategy to stop cancer progression. 
Thus, scientific research on cancer treatment has made 
significant progresses in the development of new anti-
angiogenic agents that have entered into clinical practice 
alone or in combination with the standard chemo-/radio- 
therapy [9]. Anti-VEGF compounds were developed, 
such as bevacizumab and ramucirumab as well as the 
VEGF antagonist aflibercept [7]. However, despite some 
promising results in clinical trials, the blockade of VEGF 
signaling yield positive results only in a fraction of solid 
tumors, such as colorectal, lung and breast HER2+/ER+/
PR+ cancers [10, 11]. Moreover, compared to the previous 
standard of care, treatments based on angiogenesis 
inhibitors provide poor benefits in terms of progression-
free (PFS) and overall survival (OS) [12]. VEGF 
blockade could exacerbate the oxygen deprivation in the 
TM leading to a further increased hypoxic state. In these 
conditions, in vivo studies have shown that tumor blood 
vessel pruning may even stimulate cancer cells to acquire 
pro-invasive and metastatic traits, a threatening form of 
tumor adaptation to a hypoxic TM (HTM) [7, 8, 12, 13]. 
As a matter of fact, it has been shown that glioblastoma 
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patients treated with bevacizumab had a shorter OS [14].
Hypoxic tumor microenvironment, cancer 
progression and epithelial-mesenchymal 
transition
Following the observations reported above, 
it was made clear that one of the main problems in 
fighting cancer is the extreme adaptation of malignant 
cells to HTM, which promotes malignant progression, 
and confers increased resistance to chemo- and radio- 
therapies [15]. In fact, increased hypoxia was correlated 
to a high expression of markers of epithelial mesenchymal 
transition (EMT) [16-18] and hypoxic niches were 
shown to be enriched of cancer stem cells (CSCs) [19, 
20]. In summary, cancer cells within a HTM undergo to 
dramatic changes, ultimately leading to a worsening of 
their malignant behavior. Thus, nowadays the research 
is devoted towards the identification of mechanisms 
involved in the adaptation of cancer cells to the HTM 
with the aim to detect targets for novel therapeutic 
agents. A key-molecule identified in mid-nineties is the 
HIF1A [21]. HIF1A is responsible for the formation of 
HIF complex that acts as a transcription factor in the 
activation of a broad spectrum of genes orchestrating 
large phenotypic changes and ultimately leading to EMT. 
Following EMT, cells lose their normal phenotype and 
acquire mesenchymal features [22, 23] including the 
acquisition of stemness characteristics [24], enhancement 
of invasiveness and metastasizing capabilities [25]. All 
these changes are associated with poor prognosis and 
chemo-/radio-resistance in different tumor models [26, 
27]. EMT is characterized by loss of proteins involved in 
cell adhesion (e.g. E-cadherin) and the over-expression 
of mesenchymal-specific proteins such as SNAIL, the 
Vimentin, and TWIST [16, 18]. Phenotypically, these 
changes correspond to the acquisition of a spindle-like 
cell morphology, increased invasiveness, migration, 
and cell proliferation enabling cancer cells to invade 
surrounding tissues [16]. For this reason, this transition 
has been regarded as the possible first step in the 
complex process of generating distant metastases [28, 
29] (Figure 1). In parallel with these considerations, it is 
not surprising that HIF1A over-expression was showed 
to be an independent predictor of poor prognosis in most 
of the solid tumors [30-34]. The hypoxia>HIF>EMT 
axis has been studied thoroughly in aggressive tumors 
[e.g. lung, triple negative breast (TNBC), gastric, ovarian 
cancer, melanoma, multiple myeloma, malignant pleural 
mesothelioma (MPM), pancreatic ductal adenocarcinoma 
(PDAC), hepatocellular and renal cell carcinoma (RCC)] 
and various important genes activated by HIF complex 
were identified (Figure 2). Among them, there are: 
autophagy markers (BECN1 and MAP1LC3 are activated 
in lung cancer [35], in PDAC [36]); acidosis modulators 
(CAIX is overexpressed in TNBC [37], in RCC [38]); 
epigenetic regulators [39] (KLF8, CD24, JMJ2DB and 
the long-non coding RNA AK058003 are overexpressed 
in gastric cancer [40-43], CD44 in TNBC [44], NANOG, 
Figure 1: Representation of the epithelial mesenchymal transition. Cells with epithelial characteristics acquire mesenchymal 
characteristics through the activation of EMT effectors. [EMT effectors: TGFB, Hedgehog (Hh), Wnt, Jagged/Notch signalling pathways, 
SNAIL, Slug, Vimentin, TWIST, OCT4, SOX2, CAIX, AXL, MicroRNAs (miRNA) and long non-coding RNAs (lncRNA)]. 
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Figure 2: Genes whose expression was shown to be correlated to the activation status of HIF1A, leading to EMT. 
Autophagy markers: BECN1, MAP1LC3; acidosis modulators: CAIX; epigenetic regulators: KLF8, cell surface glycoproteins (CD24, 
CD44), lysine (K)-specific demethylase jumonji domain (JMJ2DB), nanog homeobox (NANOG), octamer-binding transcription factor 4 
(OCT4), SRY sex determining region Y-box 2 (SOX2), sonic hedgehog (SHH), smoothened, frizzled class receptor (SMO), GLI family 
zinc finger 1 (GLI1); long non-coding RNA: AK058003; chemokines: CXCR4, CCL2, CCR7, CX3CR1; cyclospporins: cyclophilin A 
(CYPA); endothelins: endothelin1 (EDN1); fascins: fascin actin-bundling protein 1 (FSCN1); GTPase proteins: Rho family GTPase 3 
(RND3); insulin growth factors: IGF1, IGF1R, IGFBP3; mucins: mucin 1, cell surface associated (MUC1); matrix metalloproteinase: 
MMP2, protein kinases receptors: TGFB/TGFBR1, TNFAR, AXL; HGF; adrenomedullin (ADM). 
Figure 3: Chemical structures related to Table 1. 
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OCT4, SRY, SOX2, SHH, SMO, GLI1 in PDAC [45, 46] 
and MPM [47]); chemokines (CXCR4 and CCL2 are 
over-expressed in gastric cancer [48, 49] and multiple 
myeloma [50], CCR7 in ovarian cancer [51] whereas 
CX3CR1 in PDAC [52]); cyclosporin (CYPA is over-
expressed in PDAC [53]); endothelin (EDN1 is activated 
in melanoma [54]); fascin (FSCN1 is activated in PDAC 
[55]); GTPase proteins (RND3 is over-expressed in gastric 
cancer [56]); growth factors related to insulin homeostasis 
(IGF1, IGF1R, IGFBP3 are over-expressed in lung cancer 
[57] and hepatocellular carcinoma [58]); mucins (MUC1 
is overexpressed in MPM [59], in PDAC [60], in RCC 
[61] and in lung cancer [62]); matrix metalloproteinases 
(MMP2 is over-expressed in PDAC, lung cancer and 
ovarian cancer cell lines [63]); protein kinase receptors 
(TGFB/TGFBR1 expression is up-regulated in gastric 
cancer [64], TNFAR in melanoma [65] and in RCC [66] 
and AXL in gastric cancer [67], TNBC [68], in lung cancer 
[69], and MPM [70]). Moreover, another important cell 
signaling is activated by HIF. It was shown that HGF, 
together with its ligand MET (HGF/MET), promotes 
cell proliferation, survival, migration, and angiogenesis 
in hepatocellular carcinoma [71]. Furthermore, ADM 
is overexpressed in RCC [72] and in PDAC [73]). ILK 
is activated by HIF1A and through a regulatory loop it 
is responsible for the increase of HIF1A expression, 
in a positive feed-back mechanism [74]. In addition, 
E-cadherin, which has always been defined as a tumor 
suppressor, showed an unexpected role in the regulation 
of genes involved in the response to hypoxia, suggesting 
a possible novel function in aggressive breast cancer 
[75]. These recent findings, taken together, prompted 
clinical researchers to focus on the identification of new 
compounds able to inhibit HIF1A or its targets. Hereon, 
we will focus on novel therapeutic agents developed for 
these purposes and for which the clinical trials are in an 
advanced stage (Table 1, Figure 3). These new molecules 
could open the way to effective therapies and increase the 
survival of patients suffering from these aggressive types 
of cancer.
Table 1: Summary of novel therapeutic approaches
Drugs Targets Phase Type of cancer Ref. study
a. Targeting HIF1A
Digoxin/
DIG-HIF HIF1A 2 Advanced breast cancer NCT01763931
Ganetespib HIF1A/Hsp90 3 Advanced NSCLC NCT01798485
b. Inhibiting HIF-targets involved in the regulation of acid TM
SLC-0111 CAIX 1 Advanced solid tumors NCT02215850
DTP348 CAIX 1 Advanced solid tumors NCT02216669
c. Inhibiting HIF-targets involved in the Epithelial Mesenchymal Transition
Rilotumumab MET/HGF/SF 3 Advanced gastric cancer NCT01697072
Crizotinib
Axitinib MET/ALK 1b Advanced solid tumors NCT01999972
Cabozantinib MET/AXL RET/ROS1/NTRK1 2 Advanced NSCLC NCT01639508
d. Targeting mitochondrion dysfunction
CPI-613 Mitochondria 1 Metastatic colorectal cancer NCT02232152
Fenofibrate Mitochondria 2 Advanced multiple myeloma NCT01965834
Antibacterial 
agents Mitochondria 2 Malignant diseases NCT02366884
Anti-bacterial pro-drug activated in hypoxia
TH302 Hypoxic TM 3 Soft Tissue sarcoma NCT01440088
e. Targeting stromal-epithelial metabolic coupling 
Metformin MCT4 0 Head and Neck squamous cells cancer NCT02083692
Topotecan/ 
Acetylcysteine MCT4/CAV1 2 Advanced ovarian cancer NCT02569957
Summary of clinical trial that are currently recruiting patients targeting: HIF1A, HIF-targets involved in the regulation of 
acid TM, HIF-targets involved in the epithelial mesenchymal transition, and metabolic changes such as mitochondrion 
dysfunction and stromal-epithelial metabolic coupling.
Oncotarget5www.impactjournals.com/oncotarget
THERAPEUTIC APPROACHES IN 
ADVANCED CLINICAL TRIALS 
TARGETING THE ADAPTATION TO 
HTM
Targeting HIF1A
Digoxin/ DIG-HIF
Digoxin, a cardiac glycoside, it has been shown 
to have anti-cancer activity due to the inhibition of 
HIF1A synthesis, in vitro and in vivo in several solid 
tumors [76-78]. Currently, Digoxin is involved in a 
phase 2 clinical trial (https://clinicaltrials.gov/ct2/show/
NCT01763931) as a novel inhibitor of HIF1A in breast 
cancer. It will be administrated to breast cancer patients 
for 2 weeks prior to surgery. During the two weeks of 
daily oral digoxin therapy, researchers will measure, by 
immunohistochemistry, the expression of HIF1A protein 
in surgically resected breast cancer tissues. This clinical 
trial will be useful also to evaluate adverse events, to 
assess safety and tolerability of Digoxin in the pre-surgical 
breast cancer patients according to Common Terminology 
Criteria for Adverse Events, version 4.
Ganetespib
The chaperone Hsp90 is involved in tumor growth, 
angiogenesis and cancer stem cells formation [79, 80]. 
Its pathway leads to the activation of several oncogenic 
proteins including HIF1A. It has been shown that 
Ganetespib (5-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-
4-(1-methyl-1H-indol-5-yl)-2,4-dihydro-3H- 1,2,4-triazol-
3-one) is able to increase the proteasome-mediated 
degradation of Hsp90. By this mechanism Ganetespib can 
inhibit HIF1A in a TNBC mouse model [81]. This drug 
was already administered as mono-therapy in patients 
with genotypically defined advanced non-small cell 
lung cancer (NSCLC) in a multicenter phase 2 study and 
showed manageable side effects and an OS improvement 
of 11 months (https://www.clinicaltrials.gov/ct2/show/
record/NCT01798485) [82]. Currently, Ganetespib is in a 
phase 3 study in combination with docetaxel in patients 
with advanced NSCLC (https://www.clinicaltrials.gov/
ct2/show/NCT01798485). This clinical trial aims to the 
identification of a possible synergism between Ganetespib 
(150 mg/m2) and Docetaxel (75 mg/m2) to propose a 
more effective anti-cancer therapy than Docetaxel alone. 
Inhibiting HIF-targets involved in the regulation 
of acid TM
CAIX is a hypoxia-inducible metal-enzyme that 
promotes cancer cell survival and invasion in HTM via 
HIF activation [83]. Its role is to catalyze the reversible 
hydration of carbon dioxide to bicarbonate and protons 
(H2O + CO2 to HCO3- + H+) regulating cellular pH. It is 
expressed selectively on the cell surface of tumor cells, 
particularly in the CSCs, [83] and it is one of the major 
factors contributing to cancer cell survival and metastasis. 
CAIX is highly expressed in breast cancer and PDAC 
and it has been shown as biomarker of poor prognosis 
for metastasis development and survival [83-85]. Further 
work has established a critical role of CAIX expression 
in the maintenance of EMT phenotype [84], “stem cell” 
function and tumor heterogeneity induced by hypoxia [86, 
87].
SLC-0111
SLC-0111, as small molecule, it is able to reach the 
hypoxic niches and selectively bind and inhibit CAIX. 
Pre-clinical pharmacokinetic and toxicology analysis 
of SLC-0111 has been completed, demonstrating little 
toxicity and positive effects for the treatment of various 
tumors. Currently, SLC-0111 is involved in a phase I, 
Multi-center, Open-label, study (https://clinicaltrials.
gov/ct2/show/NCT02215850). In this prospective single 
arm study, SLC-0111 will be given once daily in 28 day 
cycles, in subjects with advanced solid tumors. The aim is 
to investigate its safety, tolerability, and pharmacokinetic 
and to gain some information about its effectiveness in 
treating cancer.
DTP348 
DTP348, namely 2-(2-methyl-5-nitro-1H-imidazol-
1-yl) ethylsulfamide, was designed to target hypoxic 
tumor regions using low doses. Interestingly, this molecule 
is able to incorporate, in the same scaffold, different 
functionalities: the inhibition of CAIX, the acidification 
of the intracellular pH, and the radio-sensitization 
in HTM [88]. This oral dual CAIX inhibitor/ radio-
sensitizer, is currently in a phase I multicenter, open-
label, dose-escalation study (https://clinicaltrials.gov/ct2/
show/NCT02216669). The clinical trial will investigate 
the effects of DTP348 alone and in combination with 
radiotherapy in patients with advanced solid tumors, to 
determine its recommended phase II Dose, safety and 
tolerability. Once defined these parameters, DTP348 will 
be administered every day for 7 weeks to evaluate its 
pharmacokinetic and anti-cancer activity. 
Inhibiting HIF-targets involved in the Epithelial 
Mesenchymal Transition
HGF is the natural ligand of MET proto-oncogene, 
a receptor tyrosine kinase [89, 90]. It has been shown that 
the activation of the HGF/MET pathway induces EMT 
generating a mesenchymal population more tumorigenic 
and chemo-resistant than the parental one [91]. HGF/MET 
are induced by HIF1A [92] and it has been shown that 
HIF1A overexpression increases HGF’s mRNA stability 
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[93]. 
Rilotumumab
Rilotumumab is a human monoclonal antibody 
immunoglobulin G type 2, that blocks the binding of 
HGF/SF to its receptor MET. Rilotumumab is currently in 
a phase 3, multicenter, randomized, double-blind, placebo 
controlled study, of epirubicin, cisplatin & capecitabine 
(ECX) or untreated advanced MET-positive gastric or 
gastroesophageal junction (GEJ) adenocarcinoma (https://
clinicaltrials.gov/ct2/show/NCT01697072). The aim of the 
study is to evaluate if the treatment of ECX in combination 
with Rilotumumab (15 mg/kg, IV every 21 days) leads 
to a better clinical outcome, evaluating OS, PFS, time 
to progression, objective response rate (ORR), disease 
control rate, time to response and immunogenicity in 
subjects with un-resettable locally advanced or metastatic 
MET positive gastric or GEJ cancer. 
Crizotinib/axitinib
The hypothesis already discussed in the first part 
of this review that MET and HGF contribute to VEGF 
inhibitor resistance, is currently tested in a phase 1b, 
open label, dose escalation study combining Axitinib 
(N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-
6-yl]sulfanyl]benzamide) with Crizotinib (3-[(1R)-1-
(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-
4-ylpyrazol-4-yl)pyridin-2-amine) in patients with 
advanced solid tumors (https://clinicaltrials.gov/ct2/
show/NCT01999972). Axitinib is a potent and selective 
tyrosine kinase inhibitor of VEGF receptor (VEGFR) 
1, 2, and 3 [94]. Crizotinib is a MET and ALK inhibitor, 
actually in use for patients with ALK-positive NSCLC 
[95]. This clinical trial is really innovative and complex, 
since this is the first time that Axitinib and Crizotinib are 
administered in combination. The first part of the study 
will be essential to evaluate if the oral administration of 
Axitinib (2-5 mg, twice daily for 28 days cycles) and 
Crizotinib (200-250 mg, twice daily for 28 days cycles) 
has an anti-cancer activity in advanced solid tumors. 
Moreover in this first part the effective dosage that will be 
administered, will be defined in advanced RCC to evaluate 
safety, pharmacokinetics and pharmacodynamics. 
Cabozantinib
Cabozantinib (1-N-[4-(6,7-dimethoxyquinolin-4-
yl)oxyphenyl]-1-N’-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide) is an oral medicine that inhibits MET, 
RET, ROS1, NTRK1, and AXL. The inhibiting activities of 
Cabozantinib towards MET and AXL is relevant. In fact, 
researchers found AXL, a member of receptor tyrosine 
kinase family [96] to increase EMT phenotype, commonly 
activated in HTM [97]. A key-role of this increased 
expression is due again by HIF that directly activates AXL 
gene transcription by binding to the hypoxia-response 
element within the AXL proximal promoter [98]. Recently, 
it has been demonstrated that increased AXL expression 
could contribute to drug resistance in cancer cell lines. 
In fact, AXL down-regulation inhibits cell survival and 
overcomes drug resistance in vitro. AXL could activate the 
downstream signals such as AKT and ERK1 to promote 
cell survival and growth. Therefore, AXL inhibitors 
could be effective in abrogating the growth of tumor 
cells [69]. Thus, through both MET and AXL inhibitions, 
Cabozantinib was shown to induce cancer shrinkage and 
cell growth reduction in medullary thyroid and prostate 
carcinoma. Currently, a phase 2 study is evaluating 
Cabozantinib in patients with RET fusion- (Group A) and 
those with ROS1 or NTRK1 fusions or increased MET 
or AXL activity (Group B) in advanced NSCLC (https://
clinicaltrials.gov/ct2/show/NCT01639508). During the 
period of 28 days cycle, 60 mg of Cabozantinib will be 
administered to patients orally daily, to evaluate positive 
and negative effects in tumors with genes changes. 
Moreover, in group A and B ORR, PFS and OS will be 
evaluated.
METABOLIC CHANGES AND 
THERAPEUTIC TARGETS
Warburg effect, mitochondria changes and cancer 
stem cells
In parallel with the adaptation to a HTM, deep 
changes are observed also in the mitochondrial functions. 
A well-known phenomenon commonly found in cancer 
cells is the so-called Warburg effect (WE). While in 
normal tissues, glucose is bio-transformed to pyruvate 
and carried into the mitochondria for the oxidative 
phosphorylation (OXPHOS) (Figure 4a), in cancer, the 
glycolysis is 200-fold more active than the normal, either 
in the presence or absence of oxygen (aerobic glycolysis/
WE) leading to high amount of lactate [99] (Figure 4b). 
Despite the first identification of the WE dates back 
to 1927, the mechanisms triggering WE are not fully 
understood, yet. It could be the consequence of damaged 
mitochondria in cancer cells, or of the adaptation of cancer 
cells to HTM. The up-regulation of the aerobic glycolysis 
seems related to oncogene activation. It appears that 
almost every major oncogene that drives oncogenesis 
also drives increased glucose metabolism. For example, 
activating mutations within BRAF, PTEN, and KRAS, 
were found to have effects in the transcriptional activation 
and repression of key metabolic enzymes and in the 
reprogramming of glutamine metabolism [100-102]. WE 
could be also triggered by the stabilization of HIF1A. In 
fact, once HIF1A is stabilized, it is observed that cancer 
cells increase glycolysis, where a good proportion of 
glucose is converted into lactate instead going through 
OXPHOS, therefore creating an acidic microenvironment 
and leading to an inefficient ATP production [103]. It 
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is well-established that this change is important for 
survival in hypoxic conditions and it correlates also with 
CSCs formation. In fact, mitochondria show differences 
between CSCs and non-CSCs. For example, CSCs from 
lung cancer and leukemia showed low mitochondrial DNA 
content, OXPHOS, oxygen consumption rate, intracellular 
ATP and an enrichment of specific biomarkers (ALDH, 
CD24, CD44, CD133) responsible for their formation 
and survival [104]. However, these facts should not 
mislead regarding to the role of mitochondria in CSCs. 
In fact, it was also observed that the clonal expansion and 
survival of CSCs is, actually, dependent on mitochondrial 
biogenesis suggesting that the mitochondrial metabolism, 
although reduced, is crucial in CSC survival. In particular, 
CSCs have been shown to be dependent on OXPHOS. 
In fact, when an inhibitor of ATP-synthase activity 
is used, CSCs usually are killed [105]. Although, a 
reduced mitochondrion activity is observed in cancer, 
in oncocytoma a paradoxical effect is observed. These 
“oxyphilic” tumors (typically RCC, ovarian or thyroid 
cancer) have an impressively abnormal number of 
mitochondria in their cytoplasm [106-109]. A model 
was proposed where cancer genes could be responsible 
for a reduced mitochondria metabolism leading to an 
inefficient ATP production, and where the mitochondrial 
hyperplasia is a consequence of a compensatory effect 
in the attempt, unsuccessful, to restore the normal ATP 
production [110]. Among the players discovered to be 
involved in WE and related metabolic changes the Hsp90 
chaperon has a role in maintaining energy production 
under nutrient deprivation [111]. Moreover, SLC2A1 and 
MCT4 were found frankly over-expressed in cancer cells 
in correlation to an improved glucose supply, and lactate 
disposal [112]. In addition, in gastric cancer also MACC1 
was found up-regulated and it was found to contribute in 
triggering the WE through the up-regulation of glycolytic 
enzymes [113]. It has been hypothesized that the changes 
in mitochondrion activity could be a weak-point for CSCs 
[114]. Thus, novel therapeutic approaches were proposed 
based on the use of antibiotics targeting mitochondrion 
[105], in the reminiscence of its prokaryotic origins. 
Five classes of mitochondrial-targeted antibiotics 
including erythromycin, tetracycline, glycylcycline, and 
chloramphenicol effectively reduce CSCs formation 
[105, 115] and similar results were obtained with 
oligomycin A, an inhibitor of the mitochondrial ATP 
Figure 4: The Warburg effect and the reverse Warburg effect. A. In normal tissues, glucose is bio-transformed to pyruvate 
and carried into the mitochondria for the oxidative phosphorylation (OXPHOS). B. Most types of cancer engage themselves in glycolysis, 
irrespective to the presence of oxygen (aerobic glycolysis or Warburg Effect). C. Some cancer cells reprogram cancer associated fibroblasts 
(CAFs) to undergo aerobic glycolysis (WE) and to secrete energy-rich nutrients that feed into mitochondrial oxidative metabolism in cancer 
cells.
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synthase [115]. When considering more in general 
specific mitochondrion inhibitors, a recent work showed 
that a specific Monocarboxylate Transporters (MCTs) 
inhibitor (AR-C155858), which blocks the cellular 
uptake of mitochondrial fuels, such as lactate, could 
effectively reduce the formation of CSCs [115]. Moreover, 
novel molecules, such as NV-128, an isoflavone-
derivative, showed a significant activity in reducing the 
mitochondrial function (with decrease in ATP, COX1, 
and COX4 levels), leading to increased mitochondrial 
superoxide and hydrogen peroxide. This promoted a state 
of cellular starvation and oxidation that activated two 
independent pathways: (i) AMPKa1 pathway leading to 
MTOR inhibition; and (ii) mitochondrial MAPK/ERK 
kinase/extracellular signal pathway, leading to loss of 
mitochondrial membrane potential [116] with an inhibition 
of CSCs formation. It should be stressed that normal cells 
appeared more resistant to these inhibitors as compared to 
CSCs. This fact should provide a wide therapeutic window 
for reducing the side effects for cancer patients. 
Reverse Warburg Effect and metabolic symbiosis
Once the research on cancer metabolism advances, 
it was found that WE is not a general rule. In fact, they 
are highly flexible in adapting to the micro-environmental 
conditions and they can easily reactivate the mitochondrial 
OXPHOS [117]. Differences in the metabolic phenotype 
can even occur within a single tumor mass [118]. Thus, 
for some tumors, cancer cells are found not completely 
dependent on accelerated glycolysis. Interestingly, it was 
discovered that they are “fed” through the activation of 
normal stromal cells surrounding cancer cells [119]. For 
example, it has been shown that the activation of HIF1A 
occurs in carcinoma-associated fibroblasts (CAFs) and it 
enhances aerobic glycolysis and lactate production, which 
is converted to pyruvate and utilized for mitochondrial 
OXPHOS in cancer cells [120, 121]. This phenomenon 
has been called ‘‘reverse WE’’ (RWE), which indicates 
increased aerobic glycolysis of stromal cells (CAFs) 
adjacent to cancer cells, which secrete energy-rich 
nutrients that feed cancer cells [122], leading to an acidic 
TM, increased tumor growth and malignant behaviors 
[123]. This host-parasite relationship is characterized also 
by the loss of caveolin-1 (CAV1), a molecule that has been 
shown to be responsible for HIF1A activation in stromal 
cells [120] and by the increase of MCTs and in particular 
MCT4, a transporter responsible for the regulation of both 
energetic supply and intracellular pH [124] (Figure 4c). 
Based on this consideration, the development of anticancer 
agents that target the enzymes involved in glycolysis 
appears to be promising.
NOVEL THERAPEUTIC APPROACHES 
TARGETING METABOLIC CHANGES
Targeting mitochondrion dysfunction
The mitochondrion changes discussed in the last 
two sections prompted clinical researchers to focus on the 
identification of new compounds able to inhibit some of 
the involved molecules. Hereon, we will describe novel 
therapeutic agents developed to these purposes (Table 1, 
Figure 3). 
CPI-613
CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) is a 
molecule able to kill cancer cells through the shutdown of 
mitochondria. Consequently the deprivation of energy and 
other supplies, lead to the inhibition of cell growth. CPI-
613 is currently involved in a pilot phase I trial (https://
clinicaltrials.gov/ct2/show/NCT02232152) in combination 
with fluorouracil in patients with non-resettable 
metastatic colorectal cancer. The aim of the study is to 
evaluate if there is a synergism between a chemotherapy 
drug (fluorouracil, administered IV over 46 hours on 
days 2-4) and an inhibitor of mitochondria (CP-613, 
administered IV over 2 hours on days 1-4) to determine 
the Maximum Tolerated Dose, pharmacokinetic and safety 
in patients who have failed FOLFOX (leucovorin calcium, 
fluorouracil and oxaliplatin), or FOLFIRI (leucovorin 
calcium, fluorouracil, and irinotecan hydrochloride) 
therapies.
Fenofibrate
Fenofibrate (propan-2-yl 2-[4-(4-chlorobenzoyl)
phenoxy]-2-methylpropanoate), that is currently in use to 
treat hyperlipoproteinemia (i.e high level of cholesterol 
and/or triglycerides) [125], has been shown to inhibit 
mitochondrial function by blocking ATP synthesis and 
inhibiting electron transport at NADH-ubiquinone (UQ) 
oxidoreductase. This inhibition leads to the induction of a 
stress signal known as the unfolded protein response and 
subsequently apoptosis, in particular in multiple myeloma. 
Thus fenofibrate is now studied in a phase II clinical trial 
(https://clinicaltrials.gov/ct2/show/NCT01965834) with 
the aim to determine response rate, safety and tolerability 
in multiple myeloma patients.
Anti-bacterial agents
A combination of two selected antibiotics from 
doxycycline, paramomycin, clarithromycin, clindamycin, 
dapsone, miltefosine, targeting mithocondria and with 
documented anti-cancer properties are currently employed 
in a phase 2 clinical trial (https://clinicaltrials.gov/ct2/
show/study/NCT02366884) alone and/or in combination 
with anti-fungal and anti-protozoal agents. The aim of this 
study is to investigate the clinical efficacy of these agents 
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in patients with malignant disease confirmed histologically 
that is considered untreatable, progressive and fatal within 
the next 16 months. Tumor regression is expected within 
6 months of treatment and to avoid tumor recurrence the 
treatment will be continued until 10-12 months. This drug 
repositioning is interesting because we already know 
safety, tolerability and side effects.
Anti-bacterial pro-drug activated in hypoxia: TH-302
TH-302 is a prodrug that is activated only under 
hypoxic conditions; this characteristic prevents the 
production of a broad systemic toxicity, typical of 
chemotherapy. Within regions of tumor hypoxia, TH-302 
releases a potent DNA alkylating agent called bromo-
isophosphoramide mustard [126] that is responsible for 
blocking the replication and transcription of DNA, leading 
to cancer cell growth inhibition. Moreover, once TH-302 
is activated in hypoxia, it can diffuse to surrounding 
regions inhibiting the cell growth also in oxygenated 
cancer tissues, via a “bystander effect” [127]. To date, 
TH-302 is involved in a randomized phase 3, multicenter, 
open-label study, in combination with Doxorubicin in 
patients with locally advanced un-resettable or metastatic 
soft tissue sarcoma (https://clinicaltrials.gov/ct2/show/
NCT01440088). The clinical trial aims to evaluate if 
Doxorubicin that usually has poor tissue penetration and 
acts in regions of tumors that are located in proximity 
to the tumor vessels, in combination with TH-302 
could increase the OS in patients with cancers where 
the presence of hypoxia is high, as shown in soft tissue 
sarcomas [128]. TH-302 will be administered by IV 
infusion on day 1 and 8 for 21-days. Doxorubicin will 
be administered on day 1, after the TH-302 infusion. The 
pharmacokinetics of each compound will be investigated.
Targeting stromal-epithelial metabolic coupling 
(RWE)
Metformin
Metformin (1,1-Dimethylbiguanide) is an 
antidiabetic medication used particularly for the treatment 
of type 2 diabetes, decreasing hyperglycemia primarily by 
suppressing gluconeogenesis. Recently metformin is used 
also for the polycystic ovary syndrome in patients with 
insulin resistance [129]. Currently metformin is involved 
in a phase 0 clinical trial (https://clinicaltrials.gov/ct2/
show/study/NCT02083692 ) in patients with head and 
neck squamous cell cancer. The main purpose of the study 
is to evaluate if metformin is responsible for a decrease 
of MCT4 expression in fibroblast and its effect on tumor 
metabolism. 
Topotecan/ acetylcysteine
Topotecan (9-Dimethylaminomethyl-10-
hydroxycamptothecin) is an anticancer agent used 
in particular for the treatment of ovarian cancer. 
Acetylcysteine (N-Acetyl-L-cysteine) is used mainly as a 
mucolytic agent and it seems to block stromal induction 
of MCT4 [130]. Currently a phase 2 study (https://
clinicaltrials.gov/ct2/show/study/NCT02569957) is 
recruiting patients with ovarian cancer. The aim of this 
study is to evaluate if the administration of acetylcysteine 
in combination with topotecan, can inhibit the cancer cell 
growth, due to changes in MCT4, CAV1 and HIF1A. 
CONCLUSIONS
Tumor hypoxia is responsible for radio- and 
chemo-resistance as well as predisposing for increased 
CSCs formation and tumor metastases. Pro-angiogenic 
factors are synthesized and released from tumor, stromal, 
endothelial, and myeloid cells in response to HTM which 
are commonly found during cancer progression. The 
formation of an aberrant and heterogeneous vascular 
network is a key pathological event in the multistep 
process of tumor growth and metastasis. The use of VEGF 
inhibitors, such as avastin, gives some results, especially 
in colorectal, breast, lung cancer and glioblastoma where 
it is able to induce vascular normalization and reducing 
hypoxia (leading to improved efficacy of conventional 
therapies) [131] nevertheless anti-angiogenic drugs have 
been shown not to be always effective in the treatment 
of cancer, particularly for the highly aggressive ones 
[12]. These considerations have raised the questions that 
probably angiogenesis is not the main responsible of the 
tumor progression, shifting the focus on the metabolic 
changes associated with HTM. It has been thought that 
inhibiting the response to acidosis and hypoxia and 
blocking the proteins strictly correlated to HIF1A, EMT 
and mitochondria functions could be a promising way 
to treat this disease and worth to be further investigated. 
The clinical trials described in this review will provide 
in relatively short time new answers to the researchers of 
whether this approach will yield results worth to be fully 
undertaken. 
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